Cancer Immunology Research
Category: Publication
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies
Cell Reports Medicine
Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody™), in metastatic castration resistant prostate cancer patients
American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) San Francisco, CA February 16-18, 2023.
LAVA-051, a novel bispecific gamma-delta T-cell engager (Gammabody™), in relapsed/refractory MM and CLL: pharmacodynamic and early clinical data
Mechanism of action of LAVA-051, a bispecific Vγ9Vδ2 T-cell engager, confirmed in the clinical setting
Submitted for presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
Frontiers in Immunology publication, Saura-Esteller, et al.
Phase I dose escalation of LAVA-051, a novel bispecific γδ-T cell engager (Gammabody™), in relapsed/refractory hematological malignancies
European Hematological Association (EHA) 2022 Congress presentation Broijl, et al.
Phase I dose escalation of LAVA-051, a novel bispecific gamma delta T-cell engager (Gammabody™), in relapsed/refractory hematological malignancies
2022 American Society of Clinical Oncology (ASCO) Annual Meeting presentation
Brojil, et al.
Potent anti-tumor activity against patient CLL, MM and AML cells by LAVA-051, a bispecific Vγ9Vδ2-T and type 1 NKT cell engager targeting CD1d
Roeland Lameris, Jurjen M Ruben, Iris de Weerdt, Rob Roovers, Arnon P Kater, Thilo Riedl, Victoria Iglesias, Benjamin Winograd, Ton EP Adang, Tanja D de Gruijl, Paul WHI Parren, Hans J van der Vliet
A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia (Clinical Cancer Research)
Although considerable progress has been made with autologous T cell–based therapy in B-cell malignancies, application in chronic lymphocytic leukemia (CLL) lags behind due to disappointing response rates as well as substantial toxicity that is of particular concern in the elderly CLL population. Vγ9Vδ2-T cells form a conserved T-cell subset with strong intrinsic immunotherapeutic potential, largely because of their capacity to be triggered by phosphoantigens that can be overproduced by CLL and other malignant cells. Specific activation of Vγ9Vδ2-T cells by a bispecific antibody may improve the efficacy and toxicity of autologous T-cell–based therapy in CLL. Link to full article